163
Participants
Start Date
October 31, 2005
Primary Completion Date
January 31, 2012
Study Completion Date
January 31, 2012
activated recombinant human factor VII
Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Fresh frozen plasma (Source unspecified)
Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Plasma-derived FVII (LFB)
Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Prothrombin Complex conc. (PCC)
Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Plasma-derived FVII conc. (pdFVII Baxter)
Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Plasma-derived FVII conc. (pdFVII PFL)
Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
Novo Nordisk Investigational Site, Bangkok
Novo Nordisk Investigational Site, Belgrade
Novo Nordisk Investigational Site, Vouliagment
Novo Nordisk Investigational Site, Madrid
Novo Nordisk Investigational Site, Istanbul
Novo Nordisk Investigational Site, Kfar Saba
Novo Nordisk Investigational Site, Mainz
Novo Nordisk Investigational Site, Paris La Défense Cedex
Novo Nordisk Investigational Site, Bangalore
Novo Nordisk Investigational Site, Princeton
Novo Nordisk Investigational Site, Kowloon
Novo Nordisk Investigational Site, Tehran
Novo Nordisk Investigational Site, Karachi
Novo Nordisk Investigational Site, Caracas
Novo Nordisk Investigational Site, Rome
Novo Nordisk Investigational Site, Bratislava
Lead Sponsor
Novo Nordisk A/S
INDUSTRY